{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.6","upperLimit":"17.4","value":"15.0"},{"groupId":"OG001","lowerLimit":"11.8","upperLimit":"16.4","value":"14.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"859"},{"groupId":"OG001","value":"859"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaneously once every 4 weeks in the double-blind treatment phase.","id":"OG000","title":"Zoledronic Acid"},{"description":"Participants randomized to receive denosumab 120 mg subcutaneously plus placebo to zoledronic acid intravenously once every 4 weeks in the double-blind treatment phase.","id":"OG001","title":"Denosumab"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.","title":"Percentage of Participants Who Died","type":"SECONDARY","unitOfMeasure":"percentage of participants"}